Can I Take Creatine with Crestor (Rosuvastatin)?

The direct answer

There is no established pharmacokinetic or pharmacodynamic interaction between rosuvastatin and creatine monohydrate. Rosuvastatin is eliminated largely unchanged, mainly through biliary and renal excretion, and undergoes minimal hepatic CYP450 metabolism; creatine is a small nitrogenous compound that is not a substrate for the transporters rosuvastatin depends on (OATP1B1, BCRP) and has no described effect on statin absorption or clearance. The clinically relevant issue is that creatine supplementation reliably raises serum creatinine, and rosuvastatin's FDA label calls for renal monitoring, particularly at the 40 mg dose. If a prescriber does not know a patient supplements with creatine, a creatinine rise from the supplement can be mistaken for statin-related kidney injury. Disclosure and, where relevant, a cystatin C-based kidney test resolve the ambiguity.

What rosuvastatin is and where kidneys come in

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, and is FDA-approved for LDL-cholesterol reduction and, at appropriate doses, cardiovascular risk reduction in specific populations. Unlike atorvastatin or simvastatin, which are extensively metabolized by CYP3A4, rosuvastatin undergoes limited hepatic metabolism and is excreted largely unchanged, with the FDA label describing a mixed renal and biliary elimination route (per rosuvastatin prescribing information). Because of this elimination pattern, the label recommends caution and dose limits in patients with reduced kidney function, and post-marketing reports have described proteinuria and hematuria at the highest approved dose (40 mg). The label states that rosuvastatin should not exceed 10 mg daily in patients with severe renal impairment (eGFR under 30 mL/min/1.73 m², not on hemodialysis) (per the rosuvastatin prescribing information).

The large placebo-controlled JUPITER trial (n=17,802) tested rosuvastatin 20 mg in primary prevention and reported a substantial reduction in the composite cardiovascular endpoint versus placebo, without a signal of clinically significant renal harm at that dose (NEJM, JUPITER). The dose-comparison STELLAR trial found that rosuvastatin produced greater LDL-C reductions than comparator statins across the dose range studied, with the largest reductions at the 40 mg dose (Jones et al., STELLAR); the exact percentage reduction at each dose varies by source and should be confirmed against the original trial report rather than quoted as a fixed figure here.

It is worth noting that rosuvastatin does have documented drug-drug interactions through transporter pathways. A published case report describes rhabdomyolysis and acute kidney injury in a kidney transplant recipient taking rosuvastatin together with cyclosporine and leflunomide, drugs known to inhibit the OATP1B1 transporter rosuvastatin relies on for hepatic uptake (case report, 2024). That case illustrates what a genuine pharmacokinetic interaction with rosuvastatin looks like: a shared transporter pathway with another drug. Creatine does not share that pathway, which is part of why it is not classed as an interacting substance.

What creatine does to lab values

Creatine monohydrate is stored in muscle as phosphocreatine and used as a rapid energy buffer during high-intensity effort. In the body, creatine is non-enzymatically converted to creatinine at a fairly constant rate related to muscle creatine content, and creatinine is then cleared by the kidneys (Wyss & Kaddurah-Daouk, creatine and creatinine metabolism). Supplementing with creatine increases the amount of creatine available for this conversion, which raises serum creatinine independent of any change in actual kidney filtration. Reviews of creatine pharmacology describe this creatinine rise as a well-documented, dose-related effect rather than a marker of nephrotoxicity (Persky & Brazeau, clinical pharmacology of creatine).

A systematic review and meta-analysis of controlled trials found no evidence that creatine supplementation at commonly used doses impairs measured kidney function in healthy adults, despite the creatinine rise on standard labs (De Souza e Silva et al., systematic review and meta-analysis). A separate narrative review reached a similar conclusion about the distinction between a creatinine artifact and true renal impairment (Antonio et al., common questions about creatine). The practical consequence: a person taking creatine can show a creatinine value at or above the upper end of the reference range, and a calculated eGFR that looks reduced, without any underlying kidney problem. In a statin patient, that same lab pattern is what clinicians watch for as a possible adverse effect, which is where the confusion arises.

Is there a real drug-supplement interaction, or just a lab artifact?

Based on the mechanisms described above, this is best classed as a diagnostic interference issue rather than a pharmacological interaction. Rosuvastatin's clearance and creatine's metabolism do not intersect at any transporter, enzyme, or receptor described in the available pharmacology literature. Major cholesterol management guidelines do not list creatine as an interacting agent for statins (2018 AHA/ACC cholesterol guideline).

The one area of genuine biological overlap is creatine kinase (CK), a muscle enzyme. Statins can cause myopathy, and in a minority of patients this produces marked CK elevation; a clinical review of statin-associated muscle symptoms describes this range of presentations and the difficulty of attributing CK elevations to a single cause when other factors are present (Thompson et al., statin-associated side effects). Separately, intense resistance exercise, which is common among creatine users, is well known to raise CK on its own, and creatine supplementation does not appear to be a distinct additional driver of CK beyond the exercise itself (Brancaccio et al., CK monitoring in sport medicine). A clinical article on identifying and managing muscle adverse effects during statin therapy emphasizes that exercise history and any relevant supplement use should be part of the workup before attributing a CK rise to the statin itself (risk identification for statin muscle effects). In practice, this means a person taking rosuvastatin and creatine who develops muscle pain needs a clinician who knows about both the training load and the supplement before concluding the statin is the cause.

Evidence-status interaction assessment

What to actually do about lab monitoring

Because the interaction is diagnostic rather than pharmacological, management is about information flow, not dose adjustment.

Tell your prescriber you take creatine before any blood draw that will include a metabolic panel. Without that context, a rising creatinine value cannot be interpreted correctly.

Ask about cystatin C. Cystatin C is a kidney function marker that is not influenced by muscle mass, creatine intake, or recent exercise. The 2024 KDIGO guideline for evaluating chronic kidney disease recommends cystatin C-based or combined creatinine-cystatin C equations when creatinine-based estimates are likely to be inaccurate (KDIGO 2024). For a patient taking both creatine and rosuvastatin, this is exactly that scenario.

A creatine washout before a scheduled lab draw is a reasonable, low-cost alternative if cystatin C is not available, though the sources reviewed here do not establish a precise, validated number of washout days for creatinine to fully normalize; treat any specific day count as something to confirm with the ordering clinician rather than a fixed rule.

Do not stop rosuvastatin on your own because of a creatinine change. Statins have well-documented cardiovascular benefit, and unplanned discontinuation carries its own risks. If a lab value is concerning, the appropriate next step is retesting with a creatine-independent marker or after checking with the prescriber, not self-directed discontinuation.

Dosing and timing

There is no pharmacokinetic reason to separate rosuvastatin and creatine by time of day. Rosuvastatin can be taken without regard to meals per its label, and creatine timing relative to exercise or meals does not change its metabolic pathway to creatinine. Typical creatine maintenance dosing described in the sports nutrition literature is in the range of 3-5 g per day after an optional higher loading phase (Kreider et al., ISSN position stand, 2017); higher loading doses will produce a larger creatinine rise on labs than maintenance dosing. This article does not provide individualized dosing recommendations for either substance; a prescriber or pharmacist should confirm what is appropriate for a specific patient, especially anyone with reduced kidney function or on additional lipid-lowering therapy such as fenofibrate or ezetimibe, which independently raise myopathy risk.

Populations that warrant more caution

Older adults tend to have lower baseline kidney reserve and less muscle mass, which makes creatinine-based estimates less reliable even before creatine is added; cystatin C-based testing is particularly useful here. Patients with chronic kidney disease should have rosuvastatin dosed according to the FDA label's renal impairment guidance and should generally rely on cystatin C rather than creatinine for any decisions about creatine use, since the safety data on creatine specifically in reduced kidney function is limited. Anyone on combination lipid therapy, or with a personal history of statin-associated muscle symptoms, should make sure their clinician has a full and current supplement list before muscle enzyme results are interpreted.

Evidence boundary

Established: creatine reliably raises serum creatinine without proven harm to true kidney filtration in healthy adults at studied doses; rosuvastatin's own label calls for renal monitoring at higher doses because of its excretion pathway; no shared metabolic or transporter pathway between the two has been described. Plausible but not quantified: combined creatine and rosuvastatin use may complicate interpretation of a CK elevation if muscle symptoms occur. Not established: any specific numeric threshold for creatinine normalization after stopping creatine, and any additive kidney risk from combining the two beyond what either produces alone. Readers with reduced kidney function, a history of statin myopathy, or unexplained muscle symptoms should get individualized guidance rather than apply general statements here.